Protein Technologies Ltd

Protein Technologies Ltd. (PTL) is an award-winning, biotech company established in 2010. The company provides contract research services to the biotech industry.

Since its conception it has received multiple awards and funding from the UK government’s Technology Strategy Board (now Innovate UK), Bill and Melinda Gates Foundation and The Wellcome Trust for its innovation in biotechnology.

PTL is a world-leading innovator in the fields of recombinant proteins, protein engineering, biotherapeutics, biosensors, and bioreactors. PTL operates from state-of-the-art laboratories at Manchester Science Park in the United Kingdom.

Major Achievements


World’s first ice-crystal biosensor for use in the shipment of vaccines, biotherapeutics and regenerative medicine products.


A cancer drug that emits in the infrared spectrum for use as a diagnostic and photodynamic therapy for breast cancer.


revolutionary hand-held device for identification of drugs and ‘bioinks’ for track and trace and environmental monitoring system offering unparalleled levels of security, traceability and quality assurance.


For novel fluorescent proteins in the coral triangle - a two year joint development project with Sabah Biodiversity Centre, Malaysia.

Interested in investing in our research?
Leave us a message today.
Get in touch

Rare Disease

Therapy - Welcome Trust-A novel Enzyme Replacement Therapy (ERT) for sufferers of a rare disease called Alkaptonuria (AKU) otherwise known as black bone disease. AKU was the first genetic disease identified by Garrod in 1902.

Management Team

Dr. Farid Khan


Dr. Farid Khan is an award-winning scientist and innovator who has worked in drug discovery at GlaxoSmithkline and obtained a PhD from Cambridge University. Dr. Khan has developed drugs for rare diseases, biosensors and imaging agents for cancer diagnosis and treatment. He has secured multi-million funds from private and public sources, formed key interdisciplinary collaborations with industry, academic institutions and charities including stakeholders in the UK’s healthcare agenda.

He is a visionary leader and respected scientist, with deep knowledge in the engineering & Life Sciences sectors gained through business and strong links with the bio-pharmaceutical, agri-technology and clean-technology industry, both internationally and in the UK.

Dr. Khan holds a research associate position at The University of Cambridge and The University of Manchester. He has been independently acknowledged as a leader in the UK’s healthcare business community and has a proven track record of innovation.

Dr. Tariq Ali

Chief Scientific Officer

Dr. Ali has over 20 years of academic and industrial experience in protein chemistry and molecular biology, with a specific interest and expertise in upstream and downstream protein production. He has been directly involved in the development of biosimilars, ADCs and orphan disease biologics and imaging agents for cancer diagnosis and treatment.

Moreover Dr. Ali has experience and expertise in biosensor development, anti-counterfeiting and discovery of new near infra-red fluorescent (NIRF) proteins. He previously held a senior fellowship position at the University of Manchester working on the functional characterisation of molecules associated with the extracellular matrix. This work was more notably related to translational research on developing a biologic targeted for inflammatory conditions specifically a chondroprotective agent for arthritis.

He obtained his PhD from the University of Cambridge working on DNA-protein interactions and then moved to the University of Oxford where he was involved with the functional and structural characterisation of specific members of the TGF-beta super-family of proteins. He also had worked at Cambridge consultants Ltd working on developing diagnostic probes.

Scientific Advisory Board

Professor Sir Alan Fersht

University of Cambridge

Alan Fersht is a pioneer of protein engineering, which he developed as a primary method for analysis of the structure, activity and folding of proteins. He has developed methods for the high resolution of protein folding in the sub-millisecond time-scale and has pioneered the method of Phi value analysis for studying the folding transition states of proteins.

His interests also include protein misfolding, disease and cancer. He was elected Fellow of the Royal Society in 1983, from whom he was awarded the Gabor Medal in 1991 for molecular biology, the Davy Medal in 1998 for chemistry and the Royal Medal in 2008.

He is a Foreign Associate of the United States National Academy of Sciences, a Foreign Member of the American Philosophical Society, an Honorary Foreign Member of the American Academy of Arts and Sciences and a Fellow of the Academy of Medical Sciences.

In 2003 he was knighted for his pioneering work on protein folding. In addition to his significant academic achievements, Sir Alan also has experience with Biotech startups, most notably in the spin-off of the highly successful Cambridge Antibody Technologies, acquired by AstraZeneca in 2007 for £700m.

Dr. Sophie Jackson

University of Cambridge

Sophie Jackson is a Reader in Biophysical Chemistry at Cambridge University. She completed a B.A. in Chemistry at Oxford University before starting a PhD at Imperial College, University of London which she completed in Cambridge.

She was awarded William Stone Research Fellowship (Peterhouse, Cambridge), and a Human Frontiers Science Program Organisation Postdoctoral Fellowship in the Chemistry Department at Harvard University.

She returned to Cambridge in 1995 as a Royal Society University Research Fellow. Her research focuses on different aspects of protein folding and assembly processes, and her current interests include understanding how large complex protein structures form.